Egil Støre Blix

705 total citations
20 papers, 243 citations indexed

About

Egil Støre Blix is a scholar working on Cancer Research, Pulmonary and Respiratory Medicine and Oncology. According to data from OpenAlex, Egil Støre Blix has authored 20 papers receiving a total of 243 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Cancer Research, 5 papers in Pulmonary and Respiratory Medicine and 5 papers in Oncology. Recurrent topics in Egil Støre Blix's work include Breast Cancer Treatment Studies (6 papers), Advanced Breast Cancer Therapies (3 papers) and Cancer Genomics and Diagnostics (3 papers). Egil Støre Blix is often cited by papers focused on Breast Cancer Treatment Studies (6 papers), Advanced Breast Cancer Therapies (3 papers) and Cancer Genomics and Diagnostics (3 papers). Egil Støre Blix collaborates with scholars based in Norway, Denmark and Belgium. Egil Støre Blix's co-authors include Anne Husebekk, Roy M. Bremnes, Elin Richardsen, Samer Al‐Saad, Lill‐Tove Busund, Sigve Andersen, Thomas K. Kilvær, Sigurd M. Hald, Mehrdad Rakaee and Erna‐Elise Paulsen and has published in prestigious journals such as Circulation, Journal of Clinical Oncology and Annals of Oncology.

In The Last Decade

Egil Støre Blix

19 papers receiving 241 citations

Peers

Countries citing papers authored by Egil Støre Blix

Since Specialization

Citations

This map shows the geographic impact of Egil Støre Blix's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Egil Støre Blix with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Egil Støre Blix more than expected).

Fields of papers citing papers by Egil Støre Blix

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Egil Støre Blix. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Egil Støre Blix. The network helps show where Egil Støre Blix may publish in the future.

Co-authorship network of co-authors of Egil Støre Blix

This figure shows the co-authorship network connecting the top 25 collaborators of Egil Støre Blix. A scholar is included among the top collaborators of Egil Støre Blix based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Egil Støre Blix. Egil Støre Blix is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Sacubitril/Valsartan and Prevention of Cardiac Dysfunction During Adjuvant Breast Cancer Therapy: The PRADA II Randomized Clinical Trial 2025 ·Circulation ·Torbjørn Omland, Siri Lagethon Heck, Espen Holte, (unknown), (unknown), Morten Wang Fagerland, (unknown), (unknown), Egil Støre Blix, Alf Inge Larsen, Jürgen Geisler, Geeta Gulati, Torgeir Wethal	2
2	High density of TCF1+ stem-like tumor-infiltrating lymphocytes is associated with favorable disease-specific survival in NSCLC 2024 ·Frontiers in Immunology ·(unknown), Thomas K. Kilvær, Mona Irene Pedersen, Egil Støre Blix, Ilona Urbárová, Erna‐Elise Paulsen, Mehrdad Rakaee, (unknown), Tom Dønnem, Sigve Andersen	1
3	IMPRESS-Norway: Improving public cancer care by implementing precision cancer medicine in Norway. 2023 ·Journal of Clinical Oncology ·Åslaug Helland, Sigbjørn Smeland, Hege G. Russnes, (unknown), (unknown), Pitt Niehusmann, Marte Grønlie Cameron, Egil Støre Blix, (unknown), (unknown), Daniel Heinrich, Sebastian Meltzer, Åsmund Flobak, (unknown), (unknown), (unknown), Astrid Dalhaug, Geir Olav Hjortland, Line Bjørge, Kjetil Taskén	0
4	Prenatal BRCA1 epimutations contribute significantly to triple-negative breast cancer development 2023 ·Genome Medicine ·Oleksii Nikolaienko, Hans Petter Eikesdal, (unknown), Bjørnar Gilje, Steinar Lundgren, Egil Støre Blix, (unknown), Jürgen Geisler, Stephanie Geisler, Emiel A. M. Janssen, Synnøve Yndestad, Laura Minsaas, Beryl Leirvaag, Reidun Lillestøl, Stian Knappskog, Per Eystein Lønning	13
5	103P Impact of Prosigna test on treatment decision in lymph node-negative early breast cancer: A prospective multicenter study (EMIT1) 2023 ·ESMO Open ·Hege O. Ohnstad, Elin Borgen, E. Mortensen, (unknown), Lars A. Akslen, Emiel A. M. Janssen, Gry Aarum Geitvik, (unknown), Anita Langerød, (unknown), Egil Støre Blix, Sunil Xavier Raj, Hans Petter Eikesdal, Bjørnar Gilje, Helle Kristine Skjerven, (unknown), Kristin V. Reinertsen, Ragnhild Sørum Falk, (unknown), Bjørn Naume	1
6	503P The IMPRESS-Norway trial: Improving public cancer care by implementing precision cancer medicine in Norway 2022 ·Annals of Oncology ·Åslaug Helland, (unknown), (unknown), (unknown), Egil Støre Blix, (unknown), (unknown), (unknown), Bjørn Tore Gjertsen, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown)	1
7	Prototype precision oncology learning ecosystem: Norwegian precision cancer medicine implementation initiative. 2022 ·Journal of Clinical Oncology ·Kjetil Taskén, Hege G. Russnes, Åslaug Helland, Eline Aas, Line Bjørge, Egil Støre Blix, Espen Enerly, (unknown), Åsmund Flobak, Bjørnar Gilje, Bjørn Tore Gjertsen, Tormod Kyrre Guren, (unknown), Eivind Hovig, Randi Hovland, Per Eystein Lønning, (unknown), Hilde Nilsen, Steinar Thoresen, Sigbjørn Smeland	1
8	Rationale and design of the PRevention of cArdiac Dysfunction during Adjuvant breast cancer therapy (PRADA II) trial: a randomized, placebo-controlled, multicenter trial 2021 ·Cardio-Oncology ·(unknown), Geeta Gulati, Siri Lagethon Heck, Espen Holte, (unknown), (unknown), Egil Støre Blix, Jürgen Geisler, Torgeir Wethal, Torbjørn Omland	26
9	Low Z‐4OHtam concentrations are associated with adverse clinical outcome among early stage premenopausal breast cancer patients treated with adjuvant tamoxifen 2020 ·Molecular Oncology ·(unknown), Bjørn Naume, Steinar Hustad, Ersilia Bifulco, Jan Terje Kvaløy, Anna Barbro Sætersdal, Marit Synnestvedt, Tone Hoel Lende, Bjørnar Gilje, Ingvil Mjaaland, (unknown), Egil Støre Blix, Gro Wiedswang, Elin Borgen, Daniel L. Hertz, (unknown), Gunnar Mellgren, Håvard Søiland	9
10	Observational study of everolimus plus exemestane in postmenopausal women with hormone receptor-positive, HER2-negative advanced breast cancer 2019 ·Acta Oncologica ·Lars Ottestad, (unknown), (unknown), (unknown), Hans Petter Eikesdal, Egil Støre Blix, Marianne Ewertz	1
11	Neoadjuvant endocrine therapy with palbociclib in patients with high-risk breast cancer 2019 ·Annals of Oncology ·Per Eystein Lønning, (unknown), Egil Støre Blix, Steinar Lundgren, G. Vagstad, (unknown), Bjørnar Gilje, Emiel A. M. Janssen, Jürgen Geisler, Turid Aas, Hildegunn S. Aase, Stian Knappskog, Hans Petter Eikesdal	1
12	Dosimetric assessment of an Atlas based automated segmentation for loco-regional radiation therapy of early breast cancer in the Skagen Trial 1: A multi-institutional study 2017 ·Clinical and Translational Radiation Oncology ·(unknown), Giulio Francolini, Mette S. Thomsen, Esben Svitzer Yates, (unknown), Carine Kirkove, Claus Kamby, Egil Støre Blix, Mette Holck Nielsen, (unknown), Martin Berg, Birgitte Vrou Offersen	9
13	LAG-3 in Non–Small-cell Lung Cancer: Expression in Primary Tumors and Metastatic Lymph Nodes Is Associated With Improved Survival 2017 ·Clinical Lung Cancer ·Sigurd M. Hald, Mehrdad Rakaee, Iñigo Martínez, Elin Richardsen, Samer Al‐Saad, Erna‐Elise Paulsen, Egil Støre Blix, Thomas K. Kilvær, Sigve Andersen, Lill‐Tove Busund, Roy M. Bremnes, Tom Dønnem	58
14	Quality assessment of delineation and dose planning of early breast cancer patients included in the randomized Skagen Trial 1 2017 ·Radiotherapy and Oncology ·Giulio Francolini, Mette S. Thomsen, Esben Svitzer Yates, Carine Kirkove, Ingelise Jensen, Egil Støre Blix, Claus Kamby, Mette Holck Nielsen, Mechthild Krause, Martin Berg, Ingvil Mjaaland, Andreas Schreiber, (unknown), (unknown), Birgitte Vrou Offersen	13
15	Raiders of the lost mark – endothelial cells and their role in transplantation for hematologic malignancies 2016 ·Leukemia & lymphoma ·Egil Støre Blix, Anne Husebekk	8
16	Internal and external validation of an ESTRO delineation guideline – dependent automated segmentation tool for loco-regional radiation therapy of early breast cancer 2016 ·Radiotherapy and Oncology ·(unknown), Esben Svitzer Yates, (unknown), Mette S. Thomsen, Hanne Melgaard Nielsen, Philip Poortmans, Carine Kirkove, Mechthild Krause, Claus Kamby, Ingvil Mjaaland, Egil Støre Blix, Ingelise Jensen, Martin Berg, Ebbe Laugaard Lorenzen, (unknown), Birgitte Vrou Offersen	40
17	Content of Endothelial Progenitor Cells in Autologous Stem Cell Grafts Predict Survival after Transplantation for Multiple Myeloma 2015 ·Biology of Blood and Marrow Transplantation ·Egil Støre Blix, Anders Benjamin Kildal, (unknown), Anders Waage, June H. Myklebust, Arne Kolstad, Anne Husebekk	5
18	A longitudinal study of maternal endothelial function, inflammatory response and uterine artery blood flow during the second half of pregnancy 2015 ·Acta Obstetricia Et Gynecologica Scandinavica ·Kari Flo, Egil Støre Blix, Anne Husebekk, (unknown), (unknown), Tom Wilsgaard, Åse Vårtun, Ganesh Acharya	20
19	Phospho-specific flow cytometry identifies aberrant signaling in indolent B-cell lymphoma 2012 ·BMC Cancer ·Egil Støre Blix, Jonathan M. Irish, Anne Husebekk, Jan Delabie, Lise Forfang, Anne Tierens, June H. Myklebust, Arne Kolstad	19
20	Birth outcomes in primiparous women who were raped as adults: a matched controlled study 2010 ·BJOG An International Journal of Obstetrics & Gynaecology ·Hilde Nerum, Lotta Halvorsen, Pål Øian, Tore Sørlie, Bjørn Straume, Egil Støre Blix	15

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact